Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dupilumab on Nasal Epithelial Barrier Function in Chronic Rhinosinusitis With Nasal Polyps
2023-509815-10-00Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis (CRS) and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD) (3 arms), sponsored by Medical University of Vienna. Started May 2024; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)chronic rhinosinusitis (CRS)nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)
Beyond the preview
Go deeper on 2023-509815-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509815-10-00.